William Clark, MD
Hematology & Oncology · Richmond, VANPI 1891903696
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,155 of the $3,310 with a category attached, or 65.1%. Kadmon Pharmaceuticals LLC accounts for 65.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $2,180 and has fallen 78.0% since, to $479 in 2025.
Across 15 payments — averaging $220.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kadmon Pharmaceuticals LLC$2K
- E.r. Squibb & Sons, L.L.C.$258
- Gilead$223
- Janssen Research & Development, LLC$146
- Incyte Corporation$130
- Novartis$100
- plus $297 from 5 others
Across 77 payments — averaging $8858.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$295K
- National Marrow Donor Program$159K
- Gilead$107K
- Deciphera Pharmaceuticals Inc.$37K
- Takeda Pharmaceuticals U.S.A., Inc.$35K
- Janssen Research & Development, LLC$33K
- plus $16K from 2 others
What the payments were for
- Consulting fees$2,15565%
- Food & beverage$99230%
- Education$1645%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kadmon Pharmaceuticals LLC | 1 | $2,155 |
| E.r. Squibb & Sons, L.L.C. | 3 | $258 |
| Gilead | 3 | $223 |
| Janssen Research & Development, LLC | 1 | $146 |
| Incyte Corporation | 1 | $130 |
| Novartis | 1 | $100 |
| AbbVie | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 1 | $88 |
| AstraZeneca | 1 | $43 |
| Genetix Biotherapeutics Inc | 1 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,310 in reported general payments places this provider in the 65th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 19 | $369,168 |
| Atovaquone | 26 | $18,948 |
| Droplet Pen NeedlePen Needle, Diabetic | 11 | $552 |
| Ondansetron Hcl | 13 | $356 |
| Montelukast Sodium | 18 | $219 |
| Prednisone | 24 | $203 |
| Acyclovir | 19 | $197 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Richmond
- Victor YazbeckRichmond$190K
- Attique SamdaniRichmond$104K
- Elke FriedmanRichmond$23K
- James KhatcheressianRichmond$23K
- Rachit KumarRichmond$12K
- Gisa SchunnRichmond$8K
- Asit PaulRichmond$7K
- Pablo GonzalezRichmond$6K
- Hashim MannRichmond$6K
- Joshua McFarlaneRichmond$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.